Fig 1.
BSC, best supportive care; mCRC, metastatic colorectal cancer; wtRAS, wild type RAS.
Table 1.
Anti-EGFR antibody doses estimated for biweekly consumption in base case mCRC treatment.
Table 2.
Direct quarterly estimated costs for each health state evaluated, in US dollars ($).
Table 3.
Estimated probability and direct costs of grade 3 and 4 adverse events for a 3-month interval, which are covered by health public system through hospitalization.
Table 4.
Baseline values in the decision analysis model and their range in the sensitivity analysis.
Table 5.
Cost-effectiveness rankings from SUS perspective.
Fig 2.
Tornado diagram showing influence of costs with vial acquisition.
CVialPanitumumab, cost of panitumumab vial; CVialCetuximab, cost of cetuximab vial; pTox_Pan, probability of reduced dose due to toxicity of panitumumab; pTox_Cet, probability of reduced dose due to toxicity of cetuximab; pMoAb_death, probability of death using monoclonal antibodies; pMoAb_BSC, probability of progression using monoclonal antibodies; number_vial_pan, number of panitumumab vials; number_vial_cet, number of panitumumab vials.
Fig 3.
One-way deterministic sensitivity analysis related to price of 100 mg Cetuximab vial.
CVialCetuximab, Cost of vial cetuximab; BSC, best supportive care; WTP, willingness to pay.
Fig 4.
One-way deterministic sensitivity analysis related to price of 100 mg Panitumumab vial.
CVialPanitumumab, Cost of vial panitumumab; BSC, best supportive care; WTP, willingness to pay.